Archives

What My Diagnosis Taught Me About Slowing Down With Purpose

Before Huntington’s disease entered my life, I moved through the world at a pace that made sense for the life I thought I was building. I held onto the idea […]

uniQure Announces Meeting with FDA

January 9, 2026 7:05 AM EST uniQure Announces Type A Meeting Scheduled with FDA LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading […]

An Update from LoQus23

LoQus23 Therapeutics is a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myotonic dystrophy type […]

New Phase 1 POINT-HD Study

New Phase 1 POINT-HD study starts for selective huntingtin-lowering approach Dear Huntington’s community leaders, Following your request to receive updates about our research efforts, we are pleased to share that […]

How to Advocate for Yourself in Medical Settings

One of the hardest parts of living with Huntington’s disease isn’t the symptoms themselves, it’s navigating the medical system. From rushed appointments to misunderstanding symptoms, to being doubted or dismissed […]

Summary of “EHDN Platform Meeting on uniQure topline results: Unpacking the outcomes so far”

Warsaw, November 19th, 2025. Dear members, As you might know, yesterday the European Huntington’s Disease Network (EHDN) developed a seminar about the topline results of uniQure, a pharmaceutical company that […]

Finding Gratitude in a Body That Feels Unpredictable

There are mornings when I wake up and my body feels like a stranger. Some days, the movements are gentle, barely a whisper under the surface. Other days, they arrive […]

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

November 3, 2025 Dear Huntington’s Disease Community, We issued a press release today announcing that uniQure received feedback from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics […]

ADORE-DH – Potential Stem Cell Therapy

ADORE-DH was a Phase II trial of a potential stem cell therapy for HD. Sponsored by AZIDUS Brasil (a full-service clinical research organization), this randomized, double-blind, placebo-controlled study aimed to […]

How to Talk About HD Without Feeling Like a Burden

Before I speak about Huntington’s disease, there’s often a pause in my chest. It’s not just the facts I’m weighing it’s the fear of how they’ll land. Will the listener’s […]